Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer’s disease

Background: Alzheimer’s disease (AD) is the most common cause of dementia in older patients. Rivastigmine (RV, Exelon, Novartis), a reversible cholinesterase inhibitor, improves clinical manifestations of AD and may enhance ACh-modulated electroencephalogram (EEG) alpha frequency. This pilot study a...

Descripción completa

Detalles Bibliográficos
Autores principales: Moretti, Davide V., Frisoni, Giovanni B., Binetti, Giuliano, Zanetti, Orazio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107674/
https://www.ncbi.nlm.nih.gov/pubmed/25100996
http://dx.doi.org/10.3389/fnagi.2014.00179

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107674/
https://www.ncbi.nlm.nih.gov/pubmed/25100996
http://dx.doi.org/10.3389/fnagi.2014.00179

Ejemplares similares